Metabolic control of antifungal drug resistance

被引:24
|
作者
Robbins, Nicole [1 ]
Collins, Cathy [1 ]
Morhayim, Jess [1 ]
Cowen, Leah E. [1 ]
机构
[1] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
Antifungal drug resistance; Saccharomyces cerevisiae; Candida albicans; Azole; Hsp90; Calcineurin; Tor; Threonine; Nutrient signaling; Erg3; SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CALCINEURIN; EVOLUTION; HSP90; GROWTH; PATHWAY; MECHANISMS;
D O I
10.1016/j.fgb.2009.07.004
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Fungi have evolved an elegant repertoire of mechanisms to survive the cellular stress exerted by antifungal drugs such as azoles, which inhibit ergosterol biosynthesis inducing cell membrane stress. The evolution and maintenance of diverse resistance phenotypes is contingent upon cellular circuitry regulated by the molecular chaperone Hsp90 and its client protein calcineurin. Here, we establish a novel role for nutrients and nutrient signaling in azole resistance. The vulnerability of Saccharomyces cerevisiae azole resistance phenotypes to perturbation was contingent upon specific auxotrophies. Using strains that acquired azole resistance by Erg3 loss of function as a model for resistance that depends on cellular stress responses, we delineated genetic and environmental factors that mitigate the translation of genotype into resistance phenotype. Compromising a global regulator that couples growth and metabolism to environmental cues, Tor kinase, provides a powerful strategy to abrogate drug resistance of S. cerevisiae and Candida albicans with broad therapeutic potential. (c) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:81 / 93
页数:13
相关论文
共 50 条
  • [41] Molecular mechanisms governing antifungal drug resistance
    Yunjin Lee
    Nicole Robbins
    Leah E. Cowen
    npj Antimicrobials and Resistance, 1 (1):
  • [42] Antifungal drug resistance in molds: Clinical and microbiological factors
    Laura Alcazar-Fuoli
    Juan L. Rodríguez-Tudela
    Emilia Mellado
    Current Fungal Infection Reports, 2008, 2 (1) : 36 - 42
  • [43] MECHANISMS AND CLINICAL IMPACT OF ANTIFUNGAL DRUG-RESISTANCE
    VANDEN BOSSCHE, H
    WARNOCK, DW
    DUPONT, B
    KERRIDGE, D
    SENGUPTA, S
    IMPROVISI, L
    MARICHAL, P
    ODDS, FC
    PROVOST, F
    RONIN, O
    JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, 1994, 32 : 189 - 202
  • [44] Clinical relevance of mechanisms of antifungal drug resistance in yeasts
    Sanglard, D
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2002, 20 (09): : 462 - 470
  • [45] Transcriptional analyses of antifungal drug resistance in Candida albicans
    Lyons, CN
    White, TC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2296 - 2303
  • [46] Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment
    Pfaller, Michael A.
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (01): : S3 - S13
  • [47] Resistance to newest antifungal drug by Candida albicans observed
    不详
    FUTURE MICROBIOLOGY, 2011, 6 (11) : 1234 - 1234
  • [48] High incidence of antifungal drug resistance in Candida tropicalis
    Law, D
    Moore, CB
    Joseph, LA
    Keaney, MGL
    Denning, DW
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1996, 7 (04) : 241 - 245
  • [49] Antifungal drug resistance: limited data, dramatic impact?
    Rogers, Thomas R.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 : S7 - S11
  • [50] Antifungal Drug Resistance in Molds: Clinical and Microbiological Factors
    Alcazar-Fuoli, Laura
    Rodriguez-Tudela, Juan L.
    Mellado, Emilia
    CURRENT FUNGAL INFECTION REPORTS, 2008, 2 (01) : 36 - 42